News

Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are equally effective as first-line treatments in people with relapsing-remitting multiple sclerosis (RRMS), but Gilenya may be of slightly more benefit to those who switch from a previous injectable therapy, according to a real-world study of patients in Italy. The study, “…

MMJ Bioscience, which specializes in medical cannabis products, has filed a request with the U.S. Food and Drug Administration (FDA) to open Phase 2 clinical trials evaluating the company’s THC/CBD pharmaceutical compounds as possible treatments for symptoms of multiple sclerosis (MS). THC refers to the tetrahydrocannabinol compound, part of the…

Young adults with multiple sclerosis (MS) have higher relapse rates and respond better to Gilenya treatment compared to the overall MS population, data from a post hoc analysis of three separate trials show. The study, “Relapse Rate and MRI Activity in Young Adult Patients With Multiple…

For ambulatory multiple sclerosis patients with mobility problems, perceptions of being at risk of falling are as important as the risk due to their physical condition — and both should be tested when evaluating fall risk in this patient population, a study reports. The study, “The relationship between physiological…

A new way of interpreting inflammatory signals using the vagus nerve — which carries such signals from throughout the body to the brain — has been found, a study reports. This finding raises the possibility of having a kind of “early warning system” for inflammation, a damaging process in such…

Alkermes announced that it has received a $50 million payment from Biogen after a review of preliminary data related to the gastrointestinal tolerability of BIIB098 (diroximel fumarate), now in pivotal clinical studies as a possible treatment for relapsing forms of multiple sclerosis (MS). BIIB098, formerly known as ALKS 8700…

Researchers at the University of Missouri found that a lack of appropriate clothing designed for people with disabilities, caused by accidents or chronic diseases like multiple sclerosis (MS), can be a barrier to participation and a sense of inclusion in the workplace. Because workplace attire can be specific and…

More investment and new technological developments are needed to assist people who have limited mobility because of lower-limb paralysis. That was the major conclusion of an international study undertaken by ComRes on behalf of the Toyota Mobility Foundation. Around the world, millions of people have lower-limb paralysis. In…

Atrophy (shrinkage) of brain lesions correlates with physical disability in patients with multiple sclerosis (MS), new research reports. The study, “Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis,” was published in the Journal of Neuroimaging. Magnetic resonance imaging (MRI) scans are used routinely on MS patients…

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to…

Inhibiting an oxidative stress enzyme called myeloperoxidase protects the blood-brain barrier in a mouse model of multiple sclerosis (MS), limiting the migration of immune cells and halting their attack on nerve cells, researchers have found. Disruption of the blood-brain barrier is a hallmark of various disorders, including MS, and when…

Canada’s healthcare system is excellent for people with common ailments like diabetes or high blood pressure, but it’s “basically failing the nearly three million Canadians with rare diseases.” So says Durhane Wong-Rieger, president and CEO of the Canadian Organization for Rare Disorders (CORD), a Toronto-based network representing 102 patient advocacy…

Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement — lesser functional disability across a variety of measures — and often without the need for continuous treatment after taking Lemtrada for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…

While the treatment and care of children and teenagers with multiple sclerosis (MS) has seen many developments in recent years, there are still many challenges to overcome, according to a presentation given by Brenda Banwell, MD. Banwell, who is the chief of child neurology at the Children’s Hospital…

New results from a Phase 2 trial evaluating TG Therapeutics’ ublituximab continue to support the therapy’s efficacy in treating relapsing forms of multiple sclerosis (MS). This investigative infusion therapy is now moving into a Phase 3 study. Treatment with 450 mg of ublituximab delivered intravenously in a rapid fashion…

Oryzon Genomics will give updates on its leading investigational product ORY-2001, a brain-targeting epigenetic therapy now in a Phase 2 clinical trial recruiting multiple sclerosis patients, at a series of scientific conferences. According to a press release, these include two conferences in the United States, the 2018 BIO…

A survey of multiple sclerosis (MS) patients that looked at their sense of social identity based on their family relations — meant to help explain mood disorders like depression and anxiety seen in this population — found a clear link between the strength of family bonds and mood, a U.K. study…

PathMaker Neurosystems, which specializes in non-invasive devices to treat chronic neuromotor disorders, won the 2018 French-American Business (FAB) Award in the startup/small company category. PathMaker, based in Boston, is developed and testing MyoRegulator, a potential treatment for muscle spasticity in people with multiple sclerosis (MS), cerebral palsy and other chronic conditions.

Two groups working to collect and promote patient-reported outcomes (PROs) in research and treatment for multiple sclerosis (MS) announced they will jointly explore ways to “standardize and harmonize” these measures so as to make them more effective. The effort brings the iConquerMS People-Powered Research Network, managed by the nonprofit Accelerated Cure Project…

A chemical compound called indazole chloride promotes repair of myelin, the protective layer of nerve fibers, through “beneficial” inflammation in a mouse model of multiple sclerosis (MS), a study reports. The preclinical research, “Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in…

The temperament of patients with multiple sclerosis (MS) can have a significant impact on their health-related quality of life, a study suggests. The study, “Health-related quality of life in multiple sclerosis: temperament outweighs EDSS,” was published in the journal BMC Psychiatry. MS patients’s quality of life…

Girls given the quadrivalent human papillomavirus (HPV4) vaccination, commercialized as Gardasil, showed no increased risk of developing autoimmune diseases like multiple sclerosis (MS), according to a new Canadian study. The time since vaccination and the number of vaccine doses given also did not correlate with diagnoses of such disorders, supporting…

The American Autoimmune Related Diseases Association (AARDA) is partnering with Allegheny Health Network (AHN) and its newly opened Autoimmunity Institute — based in Pittsburgh, Pennsylvania — to study the costs of autoimmune disease to patients in the U.S., including that of just getting a correct diagnosis. AARDA, a non-profit that…

Age at disease onset, number of early relapses, and the extent of brain damage at baseline can help identify those who are at high risk of progression from relapsing-remitting multiple sclerosis into the secondary progressive phase of the disease, a new study shows. The study with that finding, “…

In general, multiple sclerosis (MS) patients are able to make and sustain healthy lifestyle changes associated with a better quality of life, a study shows. The study, “Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up,”…

A North Carolina couple living with multiple sclerosis have raised more than $20,000 so far this year to support Discovery MS, a nonprofit research initiative that is part of Duke University’s School of Medicine. Specifically, the money will support program efforts  to improve MS diagnosis and prognosis, gain a clearer understanding…

Learning impairments in multiple sclerosis (MS) are detected differently by the two most commonly used neuropsychological tests, a new study by the Kessler Foundation shows. The research, titled “Comparing the Open Trial – Selective Reminding Test results with the California Learning Verbal Test II in multiple…

Lesser time spent exercising and using large muscles can result in serious alterations in the metabolism of brain stem cells and their ability to generate new nerve cells, a study suggests. These findings can help to explain why patients with neurological disorders, such as multiple sclerosis and spinal muscular atrophy,…

A non-invasive procedure using magnetic pulses to stimulate the brain may be more effective in treating multiple sclerosis (MS) and other patients if the rate of stimulation is slowed, a new study suggests, finding that neurons “tire” with overstimulation and may fail to respond. The research, “Less might be…

Treatment with Gilenya (fingolimod) is associated with treatment satisfaction, which, in turn, is linked to a better quality-of-life in patients with relapsing-remitting multiple sclerosis (RRMS), a study has found. Gilenya, an oral disease-modifying treatment (DMT) for RRMS developed by Novartis, has been available in France since 2011. Studies have…